A
AnnaCarin Horne
Researcher at Karolinska University Hospital
Publications - 50
Citations - 8957
AnnaCarin Horne is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Macrophage activation syndrome & Hemophagocytic lymphohistiocytosis. The author has an hindex of 25, co-authored 47 publications receiving 6997 citations. Previous affiliations of AnnaCarin Horne include Boston Children's Hospital & Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.
Jan-Inge Henter,AnnaCarin Horne,Maurizio Aricò,R. Maarten Egeler,Alexandra H. Filipovich,Shinsaku Imashuku,Stephan Ladisch,Kenneth L. McClain,David Webb,Jacek Winiarski,Gritta Janka +10 more
TL;DR: HLH‐2004 chemo‐immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids, and subsequent hematopoietic stem cell transplantation is recommended for patients with familial disease or molecular diagnosis, and patients with severe and persistent, or reactivated, disease.
Journal ArticleDOI
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.
Jean-François Emile,Oussama Abla,Sylvie Fraitag,AnnaCarin Horne,Julien Haroche,Jean Donadieu,Luis Requena-Caballero,Michael B. Jordan,Omar Abdel-Wahab,Carl E. Allen,Frédéric Charlotte,Eli L. Diamond,R. Maarten Egeler,Alain Fischer,Alain Fischer,Juana Gil Herrera,Jan-Inge Henter,Filip Janku,Miriam Merad,Jennifer Picarsic,Carlos Rodriguez-Galindo,Barret J. Rollins,Barret J. Rollins,Abdellatif Tazi,Robert Vassallo,Lawrence M. Weiss +25 more
TL;DR: This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocyts and macrophage activation syndrome.
Journal ArticleDOI
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative
Angelo Ravelli,Francesca Minoia,Sergio Davì,AnnaCarin Horne,Francesca Bovis,Angela Pistorio,Maurizio Aricò,Tadej Avcin,Edward M. Behrens,Fabrizio De Benedetti,Lisa Filipovic,Alexei A. Grom,Jan-Inge Henter,Norman T. Ilowite,Michael B. Jordan,Raju Khubchandani,Toshiyuki Kitoh,Kai Lehmberg,Daniel J. Lovell,Paivi Miettunen,Kim E. Nichols,Seza Ozen,Jana Pachlopnik Schmid,Athimalaipet V Ramanan,Ricardo Russo,Rayfel Schneider,Gary Sterba,Yosef Uziel,Carol A. Wallace,Carine Wouters,Nico M Wulffraat,Erkan Demirkaya,Hermine I. Brunner,Alberto Martini,Nicolino Ruperto,Randy Q. Cron +35 more
TL;DR: Criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA) is developed.
Journal ArticleDOI
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
Paul La Rosée,AnnaCarin Horne,Melissa Hines,Tatiana von Bahr Greenwood,Rafał Machowicz,Nancy Berliner,Sebastian Birndt,Juana Gil-Herrera,Michael Girschikofsky,Michael B. Jordan,Ashok Kumar,Jan A M van Laar,Gunnar Lachmann,Kim E. Nichols,Athimalaipet V Ramanan,Yini Wang,Zhao Wang,Gritta Janka,Jan-Inge Henter +18 more
TL;DR: In this article, the authors present expert opinions derived from an interdisciplinary working group on adult HLH, sponsored by the Histiocyte Society, to facilitate knowledge transfer between physicians caring for pediatric and adult patients with HLH with the aim to improve the outcome for adult patients affected by HLH.
Journal ArticleDOI
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.
Helena Trottestam,AnnaCarin Horne,Maurizio Aricò,R. Maarten Egeler,Alexandra H. Filipovich,Helmut Gadner,Shinsaku Imashuku,Stephan Ladisch,David Webb,Gritta Janka,Jan-Inge Henter +10 more
TL;DR: To conclude, HLH-94 chemoimmunotherapy has considerably improved outcome in HLH, and collaborative efforts are needed to further reduce early mortality, HSCT-related mortality, and neurologic late effects.